Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
  • A61K51/04—Organic compounds
  • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
  • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
  • A61K51/04—Organic compounds
  • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
  • A61K51/04—Organic compounds
  • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
  • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
  • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
  • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
  • C07B59/001—Acyclic or carbocyclic compounds
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
  • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
  • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
  • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
  • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
  • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
  • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
  • C07F7/22—Tin compounds
  • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
  • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
  • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2121/00—Preparations for use in therapy
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/05—Isotopically modified compounds, e.g. labelled
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2500/00—Screening for compounds of potential therapeutic value
  • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Definitions

• the present technology is directed to compounds, compositions, and methods related to the treatment of tumors that express prostate specific membrane antigen ("PSMA").
• PSMA prostate specific membrane antigen
• the present technology is particulary suited to treat prostate cancer.
• X is I, I, I, I, At, or Sn(R 4 ) 3 ;
• R 1 , R 2 , and R 3 are each independently H, methyl, benzyl, 4-methoxybenzyl, or tert- butyl;
• R 4 is independently at each occurrence an alkyl group;
• n is 1 or 2; and
• m is 0, 1, 2, or 3.
• X is I, I, I, I, At, or Sn(R 8 ) 3 ;
• R 5 , R 6 , and R 7 are each independently H, methyl, benzyl, 4-methoxybenzyl, or tert- butyl;
• R 8 is independently at each occurrence an alkyl group;
• Wl is a bond or
• composition in a related aspect, includes a compound of Formula I or II and a pharmaceutically acceptable carrier.
• compositions for treating prostate cancer where the composition includes an effective amount of a compound of Formula I or II.
• a method includes administering a compound of Formula I or II to a subject suffering from prostate cancer.
• a method of enhancing uptake of a therapeutic agent to a tumor presenting prostate specific membrane antigen includes administering a first therapeutic agent comprising a PMSA targeting moiety and a human serum albumin binding moiety to a subject with one or more prostate cancer tumors, where the human serum albumin binding moiety includes a radionuclide; detecting distribution of the first therapeutic agent in the subject; and modifying the first therapeutic agent to provide a second therapeutic agent.
• PSMA prostate specific membrane antigen
• FIGs. 1 A-1B provide the biodistribution in male nude mice bearing PSMA+ LNCaP human tumor xenografts of 131 I-RPS-001 at 24, 48, 72 and 96 h p.i. (FIG. 1A) and of a compound of the present technology 131 I-RPS-005 at 24, 48, 72 and 96 h p.i. (FIG. IB).
• FIG. 2 provides the biodistribution of 131 I-RPS-020 at 1, 6, 12, 24 and 48 h p.i. in male nude mice bearing PSMA+ LNCaP human tumor xenografts.
• FIG. 3 provides the biodistribution of 131 I-RPS-022 at 1, 6, 12, 24 and 48 h p.i. in male nude mice bearing PSMA+ LNCaP human tumor xenografts.
• FIG. 4 provides the biodistribution of 131 I-RPS-027 at 1, 3, 6, 12, 18, 24, 48, and 72 h p.i. in male nude mice bearing PSMA+ LNCaP human tumor xenografts.
• FIG. 5 provides the results of ⁇ /CT imaging of LNCaP xenograft mice by ⁇ /CT using 124 I-RPS-027 (7.4 MBq, 200 ⁇ ).
• FIGs. 6A-6C are plots of time-activity curves for blood (FIG. 6A), tumor (FIG. 6B), and kidney (FIG. 6C) derived from biodistribution data.
• FIGs. 7A-7B provide the relative tumor-to-background ratios for tumor-to-blood (FIG. 7A) and tumor-to-kidney (FIG. 7B) further illustrating the effect of enhanced albumin- binding in tumor delivery of the respective compounds.
• the present technology provides compounds and methods for treatment of cancer expressing PSMA, and are particulary suited to treat prostate cancer.
• the compounds provided herein can be formulated into pharmaceutical compositions and medicaments that are useful in the disclosed methods. Also provided is the use of the compounds in preparing pharmaceutical formulations and medicaments.
• references to a certain element such as hydrogen or H is meant to include all isotopes of that element.
• an R group is defined to include hydrogen or H, it also includes deuterium and tritium.
• Compounds comprising radioisotopes such as tritium, 14 C, 32 P, and 35 S are thus within the scope of the present technology. Procedures for inserting such labels into the compounds of the present technology will be readily apparent to those skilled in the art based on the disclosure herein.
• substituted refers to an organic group as defined below (e.g., an alkyl group) in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms.
• Substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom are replaced by one or more bonds, including double or triple bonds, to a heteroatom.
• a substituted group is substituted with one or more substituents, unless otherwise specified.
• a substituted group is substituted with 1, 2, 3, 4, 5, or 6 substituents.
• substituent groups include: halogens (i.e., F, CI, Br, and I); hydroxyls; alkoxy, alkenoxy, aryloxy, aralkyloxy, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, and heterocyclylalkoxy groups; carbonyls (oxo); carboxylates; esters; urethanes; oximes; hydroxylamines; alkoxyamines; aralkoxyamines; thiols; sulfides; sulfoxides; sulfones; sulfonyls; pentafluorosulfanyl (i.e., SF 5 ), sulfonamides; amines; N-oxides; hydrazines; hydrazides; hydrazones; azides; amides; ureas; amidines; guanidines; enamines; imides; isocyanates; isocyan
• thiocyanates thiocyanates; imines; nitro groups; nitriles (i.e., CN); and the like.
• Substituted ring groups such as substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups also include rings and ring systems in which a bond to a hydrogen atom is replaced with a bond to a carbon atom. Therefore, substituted cycloalkyl, aryl, heterocyclyl and heteroaryl groups may also be substituted with substituted or unsubstituted alkyl, alkenyl, and alkynyl groups as defined below.
• Alkyl groups include straight chain and branched chain alkyl groups having from 1 to 12 carbon atoms, and typically from 1 to 10 carbons or, in some embodiments, from 1 to 8, 1 to 6, or 1 to 4 carbon atoms. Alkyl groups may be substituted or unsubstituted. Examples of straight chain alkyl groups include groups such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups.
• branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, tert-butyl, neopentyl, isopentyl, and 2,2- dimethylpropyl groups.
• Representative substituted alkyl groups may be substituted one or more times with substituents such as those listed above, and include without limitation haloalkyl (e.g., trifluoromethyl), hydroxyalkyl, thioalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, carboxyalkyl, and the like.
• Cycloalkyl groups include mono-, bi- or tricyclic alkyl groups having from 3 to 12 carbon atoms in the ring(s), or, in some embodiments, 3 to 10, 3 to 8, or 3 to 4, 5, or 6 carbon atoms. Cycloalkyl groups may be substituted or unsubstituted. Exemplary monocyclic cycloalkyl groups include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups.
• the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 5, 3 to 6, or 3 to 7.
• Bi- and tricyclic ring systems include both bridged cycloalkyl groups and fused rings, such as, but not limited to, bicyclo[2.1.1]hexane, adamantyl, decalinyl, and the like.
• Substituted cycloalkyl groups may be substituted one or more times with, non-hydrogen and non-carbon groups as defined above.
• substituted cycloalkyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined above.
• Cycloalkylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a cycloalkyl group as defined above. Cycloalkylalkyl groups may be substituted or unsubstituted.
• cycloalkylalkyl groups have from 4 to 16 carbon atoms, 4 to 12 carbon atoms, and typically 4 to 10 carbon atoms. Substituted cycloalkylalkyl groups may be substituted at the alkyl, the cycloalkyl or both the alkyl and cycloalkyl portions of the group. Representative substituted cycloalkylalkyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri- substituted with substituents such as those listed above.
• Alkenyl groups include straight and branched chain alkyl groups as defined above, except that at least one double bond exists between two carbon atoms. Alkenyl groups may be substituted or unsubstituted. Alkenyl groups have from 2 to 12 carbon atoms, and typically from 2 to 10 carbons or, in some embodiments, from 2 to 8, 2 to 6, or 2 to 4 carbon atoms. In some embodiments, the alkenyl group has one, two, or three carbon-carbon double bonds. Examples include, but are not limited to vinyl,
• substituted alkenyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri-substituted with substituents such as those listed above.
• Cycloalkenyl groups include cycloalkyl groups as defined above, having at least one double bond between two carbon atoms. Cycloalkenyl groups may be substituted or unsubstituted. In some embodiments the cycloalkenyl group may have one, two or three double bonds but does not include aromatic compounds. Cycloalkenyl groups have from 4 to 14 carbon atoms, or, in some embodiments, 5 to 14 carbon atoms, 5 to 10 carbon atoms, or even 5, 6, 7, or 8 carbon atoms. Examples of cycloalkenyl groups include cyclohexenyl, cyclopentenyl, cyclohexadienyl, cyclobutadienyl, and cyclopentadienyl.
• Cycloalkenylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group as defined above. Cycloalkenylalkyl groups may be substituted or unsubstituted. Substituted cycloalkenylalkyl groups may be substituted at the alkyl, the cycloalkenyl or both the alkyl and cycloalkenyl portions of the group. Representative substituted cycloalkenylalkyl groups may be substituted one or more times with substituents such as those listed above.
• Alkynyl groups include straight and branched chain alkyl groups as defined above, except that at least one triple bond exists between two carbon atoms. Alkynyl groups may be substituted or unsubstituted. Alkynyl groups have from 2 to 12 carbon atoms, and typically from 2 to 10 carbons or, in some embodiments, from 2 to 8, 2 to 6, or 2 to 4 carbon atoms. In some embodiments, the alkynyl group has one, two, or three carbon-carbon triple bonds. Examples include, but are not limited to -
• substituted alkynyl groups may be mono-substituted or substituted more than once, such as, but not limited to, mono-, di- or tri- substituted with substituents such as those listed above.
• Aryl groups are cyclic aromatic hydrocarbons that do not contain heteroatoms.
• Aryl groups may be substituted or unsubstituted.
• Aryl groups herein include monocyclic, bicyclic and tricyclic ring systems.
• aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, fluorenyl, phenanthrenyl, anthracenyl, indenyl, indanyl, pentalenyl, and naphthyl groups.
• aryl groups contain 6-14 carbons, and in others from 6 to 12 or even 6-10 carbon atoms in the ring portions of the groups.
• the aryl groups are phenyl or naphthyl.
• aryl groups includes groups containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., indanyl, tetrahydronaphthyl, and the like).
• Representative substituted aryl groups may be mono-substituted or substituted more than once.
• monosubstituted aryl groups include, but are not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or naphthyl groups, which may be substituted with substituents such as those listed above.
• Aralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined above.
• Aralkyl groups may be substituted or unsubstituted.
• aralkyl groups contain 7 to 16 carbon atoms, 7 to 14 carbon atoms, or 7 to 10 carbon atoms.
• Substituted aralkyl groups may be substituted at the alkyl, the aryl or both the alkyl and aryl portions of the group.
• Representative aralkyl groups include but are not limited to benzyl and phenethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-indanylethyl.
• Representative substituted aralkyl groups may be substituted one or more times with substituents such as those listed above.
• Heterocyclyl groups include aromatic (also referred to as heteroaryl) and non- aromatic ring compounds containing 3 or more ring members, of which one or more is a heteroatom such as, but not limited to, N, O, and S. Heterocyclyl groups may be substituted or unsubstituted. In some embodiments, the heterocyclyl group contains 1, 2, 3 or 4 heteroatoms. In some embodiments, heterocyclyl groups include mono-, bi- and tricyclic rings having 3 to 16 ring members, whereas other such groups have 3 to 6, 3 to 10, 3 to 12, or 3 to 14 ring members.
• Heterocyclyl groups encompass aromatic, partially unsaturated and saturated ring systems, such as, for example, imidazolyl, imidazolinyl and imidazolidinyl groups.
• the phrase "heterocyclyl group” includes fused ring species including those comprising fused aromatic and non-aromatic groups, such as, for example, benzotriazolyl, 2,3-dihydrobenzo[l,4]dioxinyl, and benzo[l,3]dioxolyl.
• the phrase also includes bridged poly cyclic ring systems containing a heteroatom such as, but not limited to, quinuclidyl.
• Heterocyclyl groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, thiazolidinyl, tetrahydrothiophenyl, tetrahydrofuranyl, dioxolyl, furanyl, thiophenyl, pyrrolyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, piperidyl, piperazinyl, morpholinyl, thiomorpholinyl,
• tetrahydropyranyl tetrahydrothiopyranyl, oxathiane, dioxyl, dithianyl, pyranyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, dihydropyridyl, dihydrodithiinyl,
• dihydrodithionyl dihydrodithionyl, homopiperazinyl, quinuclidyl, indolyl, indolinyl, isoindolyl,azaindolyl (pyrrolopyridyl), indazolyl, indolizinyl, benzotriazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, benzthiazolyl, benzoxadiazolyl, benzoxazinyl, benzodithiinyl,
• substituted heterocyclyl groups may be mono- substituted or substituted more than once, such as, but not limited to, pyridyl or morpholinyl groups, which are 2-, 3-, 4-, 5-, or 6-substituted, or disubstituted with various substituents such as those listed above.
• Heteroaryl groups are aromatic ring compounds containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to, N, O, and S. Heteroaryl groups may be substituted or unsubstituted.
• Heteroaryl groups include, but are not limited to, groups such as pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiophenyl, benzothiophenyl, furanyl, benzofuranyl, indolyl, azaindolyl (pyrrolopyridinyl), indazolyl, benzimidazolyl,
• imidazopyridinyl (azabenzimidazolyl), pyrazolopyridinyl, triazolopyridinyl, benzotriazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl,
• Heteroaryl groups include fused ring compounds in which all rings are aromatic such as indolyl groups and include fused ring compounds in which only one of the rings is aromatic, such as 2,3-dihydro indolyl groups.
• the phrase "heteroaryl groups" includes fused ring compounds. Representative substituted heteroaryl groups may be substituted one or more times with various substituents such as those listed above.
• Heterocyclylalkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heterocyclyl group as defined above. Heterocyclylalkyl groups may be substituted or unsubstituted. Substituted heterocyclylalkyl groups may be substituted at the alkyl, the heterocyclyl or both the alkyl and heterocyclyl portions of the group.
• heterocyclyl alkyl groups include, but are not limited to, morpholin-4-yl-ethyl, furan-2-yl-methyl, imidazol-4-yl-methyl, pyridin-3- yl-methyl, tetrahydrofuran-2-yl-ethyl, and indol-2-yl-propyl.
• Representative substituted heterocyclylalkyl groups may be substituted one or more times with substituents such as those listed above.
• Heteroaralkyl groups are alkyl groups as defined above in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined above. Heteroaralkyl groups may be substituted or unsubstituted. Substituted heteroaralkyl groups may be substituted at the alkyl, the heteroaryl or both the alkyl and heteroaryl portions of the group. Representative substituted heteroaralkyl groups may be substituted one or more times with substituents such as those listed above.
• Groups described herein having two or more points of attachment i.e., divalent, trivalent, or polyvalent
• divalent alkyl groups are alkylene groups
• divalent aryl groups are arylene groups
• divalent heteroaryl groups are divalent heteroarylene groups
• Substituted groups having a single point of attachment to the compound of the present technology are not referred to using the "ene" designation.
• chloroethyl is not referred to herein as chloroethylene.
• Alkoxy groups are hydroxyl groups (-OH) in which the bond to the hydrogen atom is replaced by a bond to a carbon atom of a substituted or unsubstituted alkyl group as defined above. Alkoxy groups may be substituted or unsubstituted. Examples of linear alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, and the like. Examples of branched alkoxy groups include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, isohexoxy, and the like.
• cycloalkoxy groups include but are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
• Representative substituted alkoxy groups may be substituted one or more times with substituents such as those listed above.
• alkanoyl and “alkanoyloxy” as used herein can refer, respectively, to -C(0)-alkyl groups and -0-C(0)-alkyl groups, each containing 2-5 carbon atoms.
• aryloyl and “aryloyloxy” refer to -C(0)-aryl groups and -0-C(0)-aryl groups.
• aryloxy and arylalkoxy refer to, respectively, a substituted or unsubstituted aryl group bonded to an oxygen atom and a substituted or unsubstituted aralkyl group bonded to the oxygen atom at the alkyl. Examples include but are not limited to phenoxy, naphthyloxy, and benzyloxy. Representative substituted aryloxy and arylalkoxy groups may be substituted one or more times with substituents such as those listed above.
• carboxylate refers to a -C(0)OH group.
• protected carboxylate refers to -C(0)0-G groups, where G is a carboxylate protecting group.
• Carboxylate protecting groups are well known to one of ordinary skill in the art. An extensive list of protecting groups for the carboxylate group functionality may be found in Protective Groups in Organic Synthesis, Greene, T.W.; Wuts, P. G. M., John Wiley & Sons, New York, NY, (3rd Edition, 1999) which can be added or removed using the procedures set forth therein and which is hereby incorporated by reference in its entirety and for any and all purposes as if fully set forth herein.
• esters refers to -COOR 70 .
• R 70 is a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
• amide (or “amido”) includes C- and N-amide groups,
• R 71 and R 72 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
• Amido groups therefore include but are not limited to carbamoyl groups (-C(0) H 2 ) and formamide groups (- HC(O)H).
• the amide is - R 71 C(0)-(Ci -5 alkyl) and the group is termed
• nitrile or "cyano" as used herein refers to the -CN group.
• Urethane groups include N- and O-urethane groups, i.e., - R 73 C(0)OR 74
• R and R are independently a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl, or heterocyclyl group as defined herein.
• R 73 may also be H.
• amine refers to - R 75 R 76 groups, wherein R 75 and R 76 are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined herein.
• the amine is alkylamino, dialkylamino, arylamino, or alkylarylamino.
• the amine is H 2 , methylamino, dimethylamino, ethylamino, diethylamino, propylamino, isopropylamino, phenylamino, or benzylamino.
• sulfonamido includes S- and N-sulfonamide groups, i.e., -S0 2 R 78 R 79
• R and R are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl,
• heterocyclylalkyl or heterocyclyl group as defined herein.
• Sulfonamido groups therefore include but are not limited to sulfamoyl groups (-S0 2 H 2 ).
• the sulfonamido is - HS0 2 -alkyl and is referred to as the "alkylsulfonylamino" group.
• thiol refers to -SH groups
• sulfides include -SR 80 groups
• sulfoxides include -S(0)R 81 groups
• sulfones include -S0 2 R 82 groups
• sulfonyls
• R° , R° ⁇ R , and R OJ are each independently a substituted or
• alkyl unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or
• heterocyclylalkyl group as defined herein.
• the sulfide is an alkylthio group, -S-alkyl.
• urea refers to -NR 84 -C(0)-NR"R 8b groups.
• R , R , and R 8b groups are independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclyl, or heterocyclylalkyl group as defined herein.
• amidine refers to -C( R 87 ) R 88 R 89 and - R 87 C( R 88 )R 89 , wherein R 87 , R 88 , and R 89 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
• guanidine refers to -NR 90 C( R 91 ) R 92 R 93 , wherein R 90 , R 91 , R 92 and R 93 are each independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.
• halogen refers to bromine, chlorine, fluorine, or iodine. In some embodiments, the halogen is fluorine. In other embodiments, the halogen is chlorine or bromine.
• hydroxyl as used herein can refer to -OH or its ionized form, -O " .
• a "hydroxyalkyl” group is a hydroxyl-substituted alkyl group, such as HO-CH 2 -.
• a range includes each individual member.
• a group having 1-3 atoms refers to groups having 1, 2, or 3 atoms.
• a group having 1-5 atoms refers to groups having 1, 2, 3, 4, or 5 atoms, and so forth.
• salts of compounds described herein are within the scope of the present technology and include acid or base addition salts which retain the desired pharmacological activity and is not biologically undesirable (e.g., the salt is not unduly toxic, allergenic, or irritating, and is bioavailable).
• the compound of the present technology has a basic group, such as, for example, an amino group,
• pharmaceutically acceptable salts can be formed with inorganic acids (such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid), organic acids (e.g. alginate, formic acid, acetic acid, trifluoroacetic acid, benzoic acid, gluconic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, naphthalene sulfonic acid, and p-toluenesulfonic acid) or acidic amino acids (such as aspartic acid and glutamic acid).
• inorganic acids such as hydrochloric acid, hydroboric acid, nitric acid, sulfuric acid, and phosphoric acid
• organic acids e.g. alginate, formic acid, acetic acid, trifluoroacetic acid, benzoic acid,
• the compound of the present technology can form salts with metals, such as alkali and earth alkali metals (e.g. Na + , Li + , K + , Ca 2+ , Mg 2+ , Zn 2+ ), ammonia or organic amines (e.g. dicyclohexylamine, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine) or basic amino acids (e.g. arginine, lysine and ornithine).
• metals such as alkali and earth alkali metals (e.g. Na + , Li + , K + , Ca 2+ , Mg 2+ , Zn 2+ ), ammonia or organic amines (e.g. dicyclohexylamine, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine) or basic amino acids (e.g. arginine
• Tautomers refers to isomeric forms of a compound that are in equilibrium with each other. The presence and concentrations of the isomeric forms will depend on the environment the compound is found in and may be different depending upon, for example, whether the compound is a solid or is in an organic or aqueous solution. For example, in aqueous solution, quinazolinones may exhibit the following isomeric forms, which are referred to as tautomers of each other:
• guanidines may exhibit the following isomeric forms in protic organic solution, also referred to as tautomers of each other:
• Stereoisomers of compounds include all chiral, diastereomeric, and racemic forms of a structure, unless the specific stereochemistry is expressly indicated.
• compounds used in the present technology include enriched or resolved optical isomers at any or all asymmetric atoms as are apparent from the depictions.
• racemic and diastereomeric mixtures, as well as the individual optical isomers can be isolated or synthesized so as to be substantially free of their enantiomeric or diastereomeric partners, and these stereoisomers are all within the scope of the present technology.
• the compounds of the present technology may exist as solvates, especially hydrates. Hydrates may form during manufacture of the compounds or compositions comprising the compounds, or hydrates may form over time due to the hygroscopic nature of the compounds.
• Compounds of the present technology may exist as organic solvates as well, including DMF, ether, and alcohol solvates among others. The identification and preparation of any particular solvate is within the skill of the ordinary artisan of synthetic organic or medicinal chemistry.
• PSMA Prostate-specific membrane antigen
• PCa prostate cancer
• PSMA Prostate-specific membrane antigen
• glioma is expressed by prostate cancer
• PSMA is expressed on the neovasculature of several other tumor types, including (but not limited to) glioma, cervical carcinoma, vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary, gastric adenocarcinoma, primary colorectal adenocarcinoma, and renal cell carcinoma.
• PSMA Prostate-specific Membrane Antigen
• PSMA prostate-specific membrane antigen
• PSMA-targeted radiotherapies Notable is the potential for dose-limiting toxicity in PSMA-targeted radiotherapies. It has been reported that PSMA is expressed at low levels in the parotid and lacrimal glands, and recent experiments have shown that PMPA can be used to displace 68 Ga-PSMA-HBED- CC from rat salivary glands. See O'Keefe DS, Bacich DJ, Heston WDW. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate. 2004;58:200-210 and Wustemann T, Nikolopoulou A, Amor- Coarasa A, et al.
• the present technology provides compounds displaying high affinity for PSMA and appropriate affinity for human serum albumin (HSA) (alternately described herein as “double targeted constructs,” “double targeted compounds,” and “dual targeting ligands”) in order to provide a higher therapeutic index and be suitable for treatment of cancer expressing PSMA by targeted alpha therapy (TAT).
• HSA human serum albumin
• TAT targeted alpha therapy
• the present technology is particulary suited to treat prostate cancer.
• Compositions are also provided that incorporating such compounds, as are methods related to the treatment of cancer expressing PSMA. Futhermore, the present technology provides a method of enhancing uptake of a therapeutic agent, such as a double targeted construct, to a tumor presenting PSMA is provided, by modifying the human serum albumin binding moiety of such agents.
• R 1 , R 2 , and R 3 are each independently H, methyl, benzyl, 4-methoxybenzyl, or tert- butyl; R 4 is independently at each occurrence an alkyl group; n is 1 or 2; and m is 0, 1, 2, or 3.
• R 1 , R 2 , and R 3 may each independently be H or tert-butyl.
• R 4 may independently at each occurrence be methyl, ethyl, propyl, propyl, or butyl.
• it may be when n is 2, then m is not 2.
• the compound of Formula I may be a compound of Formula la
• X is I, I, I, I, At, or Sn(R 8 ) 3 ;
• R 5 , R 6 , and R 7 are each independently H, methyl, benzyl, 4-methoxybenzyl, or tert- butyl;
• R 8 is independently at each occurrence an alkyl group;
• Wl is a bond or
• R 5 , R 6 , and R 7 may each independently be H or tert-butyl.
• W 1 may be a bond or a carboxylate-substututed alkylene.
• W 1 may be a bond, -NH-CH(CO(0)H)-(CH 2 ) 3 - or - H- CH(CO(0)H)-(CH 2 )4-
• R 8 is independently at each occurrence methyl, ethyl, propyl, propyl, or butyl.
• it may be X 1 is 124 I, 125 I, 131 I, or 211 At.
• the compound of Formula II may be a compound of Formula Ila
• a composition that includes any one of the aspects and embodiments of compounds of Formulas I-II and a pharmaceutically acceptable carrier.
• a pharmaceutically acceptable carrier includes carriers and/or excipients.
• a pharmaceutical composition is provided, the pharmaceutical composition including an effective amount of the compound of any one of the aspects and embodiments of compounds of Formulas I-II for treating a condition; and where the condition is cancer expressing PSMA.
• a method is provided that includes administering a compound of any one of the aspects and embodiments of compounds of Formulas I-II (e.g., such as administering an effective amount) or
• the cancer may include one or more of glioma, cervical carcinoma, vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary, gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, and prostate cancer.
• the prostate cancer may include castration resistant prostate cancer.
• Effective amount refers to the amount of a compound or composition required to produce a desired effect.
• One example of an effective amount includes amounts or dosages that yield acceptable toxicity and bioavailability levels for therapeutic (pharmaceutical) use including, but not limited to, the treatment of cancer such as prostate cancer.
• Another example of an effective amount includes amounts or dosages that are capable of reducing symptoms associated with cancer, such as, for example, reduction of the number of cancer cells in circulation.
• a "subject” or “patient” is a mammal, such as a cat, dog, rodent or primate. Typically the subject is a human, and, preferably, a human suffering from or suspected of suffering from a cancer expressing PSMA, such as prostate cancer.
• the term “subject” and “patient” can be used interchangeably.
• compositions and medicaments comprising any of the compounds disclosed herein (e.g., compounds of Formulas I-IV) and a pharmaceutically acceptable carrier or one or more excipients or fillers (collectively, such carriers, excipients, fillers, etc., will be referred to as "pharmaceutically acceptable carriers” unless a more specific term is used).
• the compositions may be used in the methods and treatments described herein.
• Such compositions and medicaments include a therapeutically effective amount of any compound as described herein, including but not limited to a compound of Formulas I-II, for treating one or more of the herein-described conditions.
• the pharmaceutical composition may be packaged in unit dosage form.
• the unit dosage form is effective in treating cancer expressing PSMA when administered to a subject in need thereof.
• cancer expressing PSMA includes one or more of glioma, cervical carcinoma, vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary, gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, and prostate cancer.
• compositions and medicaments may be prepared by mixing one or more compounds of the present technology, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, or solvates thereof, with pharmaceutically acceptable carriers, excipients, binders, diluents or the like to prevent and treat disorders associated with cancer expressing PSMA, such as prostate cancer.
• the compounds and compositions described herein may be used to prepare formulations and medicaments that prevent or treat a variety of disorders associated with such cancer.
• Such compositions can be in the form of, for example, granules, powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions.
• compositions can be formulated for various routes of administration, for example, by oral, parenteral, topical, rectal, nasal, vaginal administration, or via implanted reservoir.
• Parenteral or systemic administration includes, but is not limited to, subcutaneous, intravenous, intraperitoneal, and intramuscular, injections.
• the following dosage forms are given by way of example and should not be construed as limiting the instant present technology.
• powders, suspensions, granules, tablets, pills, capsules, gelcaps, and caplets are acceptable as solid dosage forms. These can be prepared, for example, by mixing one or more compounds of the instant present technology, or pharmaceutically acceptable salts or tautomers thereof, with at least one additive such as a starch or other additive.
• Suitable additives are sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, starch, agar, alginates, chitins, chitosans, pectins, tragacanth gum, gum arabic, gelatins, collagens, casein, albumin, synthetic or semi -synthetic polymers or glycerides.
• oral dosage forms can contain other ingredients to aid in administration, such as an inactive diluent, or lubricants such as magnesium stearate, or preservatives such as paraben or sorbic acid, or anti-oxidants such as ascorbic acid, tocopherol or cysteine, a disintegrating agent, binders, thickeners, buffers, sweeteners, flavoring agents or perfuming agents. Tablets and pills may be further treated with suitable coating materials known in the art.
• suitable coating materials known in the art.
• Liquid dosage forms for oral administration may be in the form of pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, and solutions, which may contain an inactive diluent, such as water.
• Pharmaceutical formulations and medicaments may be prepared as liquid suspensions or solutions using a sterile liquid, such as, but not limited to, an oil, water, an alcohol, and combinations of these.
• Pharmaceutically suitable surfactants, suspending agents, emulsifying agents may be added for oral or parenteral administration.
• suspensions may include oils.
• oils include, but are not limited to, peanut oil, sesame oil, cottonseed oil, corn oil and olive oil.
• Suspension preparation may also contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty acid glycerides and acetylated fatty acid glycerides.
• Suspension formulations may include alcohols, such as, but not limited to, ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and propylene glycol.
• Ethers such as but not limited to, poly(ethyleneglycol), petroleum hydrocarbons such as mineral oil and petrolatum; and water may also be used in suspension formulations.
• Injectable dosage forms generally include aqueous suspensions or oil suspensions which may be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms may be in solution phase or in the form of a suspension, which is prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. An isotonic solution will be understood as isotonic with the subject. Alternatively, sterile oils may be employed as solvents or suspending agents. Typically, the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides.
• the pharmaceutical formulation and/or medicament may be a powder suitable for reconstitution with an appropriate solution as described above.
• these include, but are not limited to, freeze dried, rotary dried or spray dried powders, amorphous powders, granules, precipitates, or particulates.
• the formulations may optionally contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
• Compounds of the present technology may be administered to the lungs by inhalation through the nose or mouth.
• suitable pharmaceutical formulations for inhalation include solutions, sprays, dry powders, or aerosols containing any appropriate solvents and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH modifiers, surfactants, bioavailability modifiers and combinations of these.
• the carriers and stabilizers vary with the requirements of the particular compound, but typically include nonionic surfactants (T weens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols.
• Aqueous and nonaqueous (e.g., in a fluorocarbon propellant) aerosols are typically used for delivery of compounds of the present technology by inhalation.
• Dosage forms for the topical (including buccal and sublingual) or transdermal administration of compounds of the present technology include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, and patches.
• the active component may be mixed under sterile conditions with a pharmaceutically-acceptable carrier or excipient, and with any preservatives, or buffers, which may be required.
• Powders and sprays can be prepared, for example, with excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
• the ointments, pastes, creams and gels may also contain excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
• Absorption enhancers can also be used to increase the flux of the compounds of the present technology across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane (e.g., as part of a transdermal patch) or dispersing the compound in a polymer matrix or gel.
• excipients and carriers are generally known to those skilled in the art and are thus included in the instant present technology. Such excipients and carriers are described, for example, in "Remingtons Pharmaceutical Sciences” Mack Pub. Co., New Jersey (1991), which is incorporated herein by reference.
• the formulations of the present technology may be designed to be short-acting, fast- releasing, long-acting, and sustained-releasing as described below.
• the pharmaceutical formulations may also be formulated for controlled release or for slow release.
• compositions may also comprise, for example, micelles or liposomes, or some other encapsulated form, or may be administered in an extended release form to provide a prolonged storage and/or delivery effect. Therefore, the pharmaceutical formulations and medicaments may be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections or as implants such as stents. Such implants may employ known inert materials such as silicones and biodegradable polymers.
• Specific dosages may be adjusted depending on conditions of disease, the age, body weight, general health conditions, sex, and diet of the subject, dose intervals, administration routes, excretion rate, and combinations of drugs. Any of the above dosage forms containing effective amounts are well within the bounds of routine experimentation and therefore, well within the scope of the instant present technology.
• Those skilled in the art are readily able to determine an effective amount by simply administering a compound of the present technology to a patient in increasing amounts until, for example, the size of a tumor decreases.
• the compounds of the present technology can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kg, a dosage in the range of about 0.01 to about 100 mg per kg of body weight per day is sufficient.
• the specific dosage used can vary or may be adjusted as considered appropriate by those of ordinary skill in the art. For example, the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to those skilled in the art.
• compositions and methods of the present technology may also be demonstrated by a decrease in the symptoms of cancer expressing PSMA, such as, for example, reduction in the volume of a tumor, such as prostate cancer-related tumor.
• compositions and methods of the present technology may also be demonstrated by a decrease in the population of cancer cells in circulation.
• test subjects will exhibit a 10%, 20%, 30%), 50% or greater reduction, up to a 75-90%), or 95% or greater, reduction, in one or more symptom(s) caused by, or associated with, the disorder in the subject, compared to placebo-treated or other suitable control subjects.
• the compounds of the present technology can also be administered to a patient along with other conventional therapeutic agents that may be useful in the treatment of cancer expressing PSMA, such as prostate cancer.
• a pharmaceutical composition of the present technology may further include an anti-cancer agent different than the compounds of Formulas I-II.
• the administration may include oral administration, parenteral administration, or nasal administration.
• the administration may include subcutaneous injections, intravenous injections, intraperitoneal injections, or intramuscular injections.
• the administration may include oral administration.
• the methods of the present technology can also comprise administering, either sequentially or in combination with one or more compounds of the present technology, a conventional therapeutic agent in an amount that can potentially or synergistically be effective for the treatment of cancer expressing PSMA, such as prostate cancer.
• a compound of the present technology is administered to a patient in an amount or dosage suitable for therapeutic use.
• a unit dosage comprising a compound of the present technology will vary depending on patient considerations. Such considerations include, for example, age, protocol, condition, sex, extent of disease, contraindications, concomitant therapies and the like.
• An exemplary unit dosage based on these considerations can also be adjusted or modified by a physician skilled in the art.
• a unit dosage for a patient comprising a compound of the present technology can vary from 1 x 10 ⁇ 4 g/kg to 1 g/kg, preferably, 1 x 10 ⁇ 3 g/kg to 1.0 g/kg. Dosage of a compound of the present technology can also vary from 0.01 mg/kg to 100 mg/kg or, preferably, from 0.1 mg/kg to 10 mg/kg.
• a compound of the present technology can also be modified, for example, by the covalent attachment of an organic moiety or conjugate to improve pharmacokinetic properties, toxicity or bioavailability (e.g., increased in vivo half-life).
• the conjugate can be a linear or branched hydrophilic polymeric group, fatty acid group or fatty acid ester group.
• a polymeric group can comprise a molecular weight that can be adjusted by one of ordinary skill in the art to improve, for example, pharmacokinetic properties, toxicity or
• Exemplary conjugates can include a polyalkane glycol (e.g., polyethylene glycol (PEG), polypropylene glycol (PPG)), carbohydrate polymer, amino acid polymer or polyvinyl pyrolidone and a fatty acid or fatty acid ester group, each of which can
• a polyalkane glycol e.g., polyethylene glycol (PEG), polypropylene glycol (PPG)
• PEG polyethylene glycol
• PPG polypropylene glycol
• carbohydrate polymer e.g., amino acid polymer or polyvinyl pyrolidone and a fatty acid or fatty acid ester group, each of which can
• Conjugates may include polyethylene amine (PEI), polyglycine, hybrids of PEI and polyglycine, polyethylene glycol (PEG) or methoxypolyethylene glycol (mPEG).
• Conjugates for use with a compound of the present technology can, in one aspect, improve in vivo half-life.
• Other exemplary conjugates for use with a compound of the present technology as well as applications thereof and related techniques include those generally described by U.S. Patent No. 5,672,662, which is hereby incorporated by reference herein.
• the present technology provides methods of identifying a target of interest including contacting the target of interest with a detectable or imaging effective quantity of a compound of the present technology.
• a detectable or imaging effective quantity is a quantity of a compound of the present technology necessary to be detected by the detection method chosen.
• a detectable quantity can be an administered amount sufficient to enable detection of binding of the labeled compound to a target of interest including, but not limited to, cancer expressing PSMA such as glioma, cervical carcinoma, vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary, gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, and/or prostate cancer.
• the target may be isolated, purified and further characterized such as by determining the amino acid sequence of a protein to which the compound of the present technology is bound.
• association and/or binding can mean a chemical or physical interaction, for example, between a compound of the present technology and a target of interest.
• associations or interactions include covalent bonds, ionic bonds, hydrophilic-hydrophilic interactions, hydrophobic-hydrophobic interactions and complexes.
• Associated can also refer generally to "binding” or “affinity” as each can be used to describe various chemical or physical interactions. Measuring binding or affinity is also routine to those skilled in the art.
• compounds of the present technology can bind to or interact with a target of interest or precursors, portions, fragments and peptides thereof and/or their deposits.
• a method of enhancing uptake of a therapeutic agent to a tumor presenting prostate specific membrane antigen includes administering a first therapeutic agent includes a PMSA-targeting moiety and a human serum albumin binding moiety to a subject with one or more cancer tumors expressing PSMA, where the human serum albumin binding moiety includes a radionuclide; detecting distribution of the first therapeutic agent in the subject; and modifying the first therapeutic agent to provide a second therapeutic agent.
• the second therapeutic agent is, of course, of a different structure than the first therapeutic agent.
• the second therapeutic agent may therefore be described as including the same PMSA-targeting moiety of the first therapeutic agent and a second human serum albumin binding moiety.
• the PMSA-targeting moiety may include a glutamate-urea-glutamate moiety or a glutamate-urea-lysine moiety.
• the cancer expressing PSMA may be one or more of glioma, cervical carcinoma, vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary, gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, and prostate cancer.
• the prostate cancer may be castration resistant prostate cancer.
• the human serum albumin binding moiety may include a 124 I- substituted, a 125 I- substituted, a 131 I-substituted, or a 211 At-substituted phenyl moiety.
• the human serum albumin binding moiety may include a 4-( 124 I)-substituted, a 4-( 125 I)-substituted, a 4-( 131 I)- substituted, or 4-( 211 At)-substituted phenyl moiety.
• the human serum albumin binding moiety may include a 1,4-phenylene where the group at the 4 position is 124 I, 125 I, 131 I, or 211 At.
• modifying the first therapeutic agent may include lengthening or shortening a hydrocarbon chain of the human serum albumin binding moiety.
• Modifying the first therapeutic agent may include conjugating a polyalkane glycol (e.g., polyethylene glycol (PEG), polypropylene glycol (PPG), methoxypolyethylene glycol (mPEG)), polyethylene amine (PEI), polyglycine, hybrids of PEI and polyglycine, carbohydrate polymer, amino acid polymer, polyvinyl pyrolidone, a fatty acid, and/or a fatty acid ester group to the human serum albumin binding moiety.
• PEG polyethylene glycol
• PPG polypropylene glycol
• mPEG methoxypolyethylene glycol
• PEI polyethylene amine
• PEI polyglycine
• hybrids of PEI and polyglycine hybrids of PEI and polyglycine, carbohydrate polymer, amino acid polymer, polyvinyl pyrolidone, a
• the conjugating step may include inserting a polyalkane glycol, polyethylene amine (PEI), polyglycine, carbohydrate polymer, amino acid polymer, polyvinyl pyrolidone, a fatty acid, a fatty acid ester group, or a combination of any two or more thereof between the PSMA-targeting moiety and the human serum albumin binding moiety.
• PEI polyethylene amine
• polyglycine polyglycine
• carbohydrate polymer amino acid polymer
• polyvinyl pyrolidone polyvinyl pyrolidone
• a fatty acid e.glycine
• a fatty acid ester group e.glycine
• the conjugating step may include conjugating a polyalkane glycol, polyethylene amine (PEI), polyglycine, carbohydrate polymer, amino acid polymer, polyvinyl pyrolidone, a fatty acid, a fatty acid ester group, or a combination of any two or more thereof at a position on the the human serum albumin binding moiety that is distal to the PSMA-targeting moiety.
• the first therapeutic agent may be a compound of Formula I or II; in any embodiment herein, the second therapeutic agent may be a compound of Formula I or II.
• the method may include administering the second therapeutic agent to a subject with one or more cancer tumors expressing PSMA and detecting distribution of the second therapeutic agent in the subject. Due to the modification of the first therapeutic agent, the second therapeutic agent may exhibit a higher tumor uptake in comparsion with non-tumor tissues of the subject than was exhibited by the first therapeutic agent. In any embodiment of the method, it may be that administering the first therapeutic agent includes parenteral administration, such as intravenous administration and/or intra-arterial administration.
• EuEK(Z).40tBu (37 mg, 46 ⁇ ) was dissolved in EtOH (4 mL). Then 10% palladium on carbon (8 mg) was added and the suspension was stirred overnight under H 2 atmosphere. The mixture was filtered through celite and the filtrate was concentrated under reduced pressure to give EuEK.40tBu as a clear oil that solidified upon standing (24 mg; 78%).
• the oil was purified by silica chromatography (50% - 90% EtOAc in hexanes) and a colorless oil was isolated from which a white solid precipitated. The oil was re-dissolved in CH 2 CI 2 , filtered and concentrated under reduced pressure to give EuO- IPBA.SnMe 3 (12) as a colorless oil (29 mg, 37%).
• Radiolabeling was carried out according to a modified version of the protocol described in Zechmann CM, Afshar-Oromieh A, Armor T, et al. Radiation dosimetry and first therapy results with a 124 I/ 131 I-labeled small molecule (MTP-1095) targeting PSMA for prostate cancer therapy.
• MTP-1095 124 I/ 131 I-labeled small molecule
• 100 ⁇ . of a 250 ⁇ g/mL solution of organnostannane precursor (e.g., any one of compounds 11-17) in EtOH was added to a vial containing 74-740 MBq (2-20 mCi) Na 124 I or Na 131 I in 30-60 ⁇ .
• 131 I-RPS-027 was prepared in 49.5% radiochemical yield from its organostannane precursor. Specific activity varied from 2-10 GBq/ ⁇ according to the starting 124 I or 131 I activity.
• the deprotection step proved to be time sensitive: for reaction times below 40 minutes, incomplete deprotection was observed, while reaction times greater than 45 minutes led to the formation of an unidentified impurity that could not be removed during purification by solid phase extraction. No significant difference in labeling yield was observed when 124 I was used in place of 131 I.
• the structure for 131 I-RPS-001 (alternately described herein as 131 ⁇ - ⁇ -1095) is provided below.
• HSA affinity determination HSA was immobilized to HPLC-grade silica by the Schiff base method as described previously and were packed into 10 mm ⁇ 2.1 mm i.d.
• Control microcolumns were prepared in the same manner but with no HSA being added during the immobilization step.
• the retention factor for each compound was measured on both an HSA microcolumn and a control column by injecting 5 uL samples that contained approximately 50 ⁇ of the compound in 0.067M potassium phosphate buffer (pH 7.4). All samples were injected in triplicate at room temperature and at 1.0 mL/min, with the phosphate buffer used as the mobile phase. Similar injections were made with samples containing sodium nitrate, which was used as a void volume marker. Elution of the injected compounds was monitored by absorbance detection.
• the dissociation constant (Kd) for each compound with HSA estimated by using the measured retention factors, after correcting for any observed retention on the control column, along with the estimated content of active HSA in the column, as based on injections made with warfarin and L-tryptophan (i.e., probes for Sudlow sites I and II of HSA). See Chen J, Hage DS. Anal Chem. 2006:78:2672-2683 (cited above) and Joseph KS, Hage DS. The effects of gly cation on the binding of human serum albumin to warfarin and L-tryptophan. J Pharm Biomed Anal. 2010;53 : 811 -818, incorporated herein by reference. The estimated precision of the Kd values was ⁇ 2-14%.
• LNCaP human prostate cancer cell line
• IC 50 values of the non-radioactive iodine- containing ligands were determined by screening in a multi-concentration competitive binding assay against 99m Tc-((7 ⁇ ,12 ⁇ 165)-l-(l-(carboxymethyl)-lH-imidazol-2-yl)-2-((l- (carboxymethyl)-lH-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13, 15-tetraazaoctadecane- 7, 12,16, 18-tetracarboxylic acid technetium tricarbonyl complex) ( 99m Tc-MIP-1427) for binding to PSMA on LNCaP cells, according to protocols described in Kelly J, Amor- Coara
• LNCaP cells were plated 48 h prior to the experiment to achieve a density of approximately 5 x 10 5 cells/well (in triplicate) in RPMI-1640 medium supplemented with 0.25% bovine serum albumin. The cells were incubated for 1 h with 1 nM 99m Tc-MIP-1427 in serum-free RPMI- 1640 medium in the presence of 0.1-10,000 nM test compounds.
• Radioactive incubation media was then removed by pipette and the cells were washed twice using 1 mL ice-cold HEPES buffer. Cells were harvested from the plates and transferred to tubes for radioactive counting using a Packard Cobra II Gamma Counter. IC 50 values were determined by nonlinear regression using GraphPad Prism software.
• mice Inoculation of mice with xenografts. All animal studies were approved by the Institutional Animal Care and Use Committee of Weill Cornell Medicine and were undertaken in accordance with the guidelines set forth by the USPHS Policy on Humane Care and Use of Laboratory Animals. Animals were housed under standard conditions in approved facilities with 12 h light/dark cycles. Food and water was provided ad libitum throughout the course of the studies. Male inbred athymic nu/nu mice were purchased from The Jackson Laboratory. For inoculation in mice, LNCaP cells were suspended at 4 x 10 7 cells/mL in a 1 : 1 mixture of PBS:Matrigel (BD Biosciences). Each mouse was injected in the left flank with 0.25 mL of the cell suspension. The mice were imaged when the tumors reached
• Tissues including blood, heart, lungs, liver, spleen, pancreas, kidneys, stomach, large and small intestines (with contents), skeletal muscle, bone, and tumor, were dissected, excised, weighed wet (Sartorius analytical balance), and counted in a Wizard automated ⁇ -counter (Perkin Elmer). A 1 %ID/g standard was counted with the tissue samples. Tissue time-radioactivity levels expressed as percent injected dose per gram of tissue (%ID/g) were determined. Blood pharmacokinetics were modeled as a dual compartment system using bi-exponential least-squares regression fit to the data. Regression method was implemented in MATLAB R2015b (MathWorks, Natick, MA).
• Table 2 below provides the results of the affinity studies for certain exemplary compounds with PMSA and human serum albumin ("USA").
• the range of affinities for PSMA was determined to be 4-40 nM, with the majority of the compounds clustered between 10 nM and 15 nM.
• RPS-OOl also known as MIP-1095
• RPS- 025 could not be eluted from the column, which prevented the calculation of a precise Kd.
• RPS-027 had a modest affinity of 11 ⁇ , while RPS-OOl, RPS-022 and RPS-026 were in the range 19-26 ⁇ .
• RPS-023 (Kd 53.2 ⁇ ) was determined to have a relatively weak affinity.
• Kidney uptake (39.09 ⁇ 2.96 %ID/g) was lower at 24 h post injection than observed for 131 I-RPS-001, but clearance was considerably slower. In combination with the comparatively low tumor uptake of approximately 10% (9.37 ⁇ 1.56 %ID/g at 24 h; 10.82 ⁇ 2.64 %ID/g at 96 h), these pharmacokinetics result in poor tumor-to-background ratios at all time points.
• I-RPS-027 showed a promising biodistribution profile over the time period studied (FIG. 4).
• Activity in the blood at 1 h post injection was 3.91 ⁇ 0.48 %ID/g, which decreased to 0.58 ⁇ 0.17 %ID/g by 24 h.
• Initial uptake was also observed in the liver (6.79 ⁇ 0.70 %ID/g; 1 h), small intestine (8.01 ⁇ 0.78 %ID/g; 1 h), large intestine (8.56 ⁇ 1.67 %ID/g; 3 h), spleen (4.13 ⁇ 1.37 %ID/g; 1 h) and heart (1.30 ⁇ 0.04 %ID/g; 1 h).
• Desirable pharmacokinetics continued to be observed at longer time points for 131 I- RPS-027 (FIG. 4). Activity in the blood remained detectable up to 48 h post injection (0.20 ⁇ 0.06 %ID/g), while tumor-to-background ratio continued to increase due to rapid clearance from the kidney (1.04 ⁇ 0.65 %ID/g at 48 h). These in vivo findings were visually recapitulated by ⁇ /CT imaging of LNCaP xenograft mice using 124 I-RPS-027. Initial uptake in the tumor, kidneys and hepatobiliary system is evident at 1 h (FIG. 5), with clearance from non-target tissue resulting in highly specific tumor targeting at 24 h and 48 h post injection.
• Time-activity curves were plotted to facilitate a greater understanding of the pharmacokinetic profile of the dual binding ligands.
• Uptake in the tumor, the blood and the kidneys is plotted in FIGs. 6A-6C.
• the highest tumor uptake is observed for 131 I-RPS-001, and the kinetics of tumor washout are similar for the three compounds with lower affinity for albumin (FIG. 6A).
• the level of activity in the tumor remains most steady in the two ligands with highest albumin binding (FIG. 6A).
• the T/K ratio of 131 I-RPS-001 does not reach 3 until nearly 96 h post injection.
• the T/K ratio of 131 I-RPS-022 also increases rapidly, particularly at earlier time points (> 1 at 12 h post injection), but this is driven more by rapid kidney clearance than by tumor uptake.
• the tumor-to-blood ratio of 131 I-RPS-027 is lower than 131 I-RPS-001 (FIG. 7B), predominantly reflecting enhanced albumin binding.
• 131 I-RPS-027 shows considerably lower kidney uptake at all time points from 1 h to 72 h post injection. See Hillier S, Rubino K, Maresca K, et al. [ 131 I]MTP-1466, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted radiotherapy of prostate cancer (PCa). J NuclMed. 2012;53(Suppl 1): 170, Chen Y, Foss CA, Byun Y, et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. JMed Chem.
• 131 I-MIP-1095 (alternately described herein as 131 I-RPS-001) and 131 I-RPS-027 at 24 h is 20-fold.
• the lower kidney uptake of 131 I-RPS-027 projects to a significantly lower absorbed dose to the kidney, and a reduced risk of relevant nephrotoxicity at therapeutic doses or under a multiple treatment cycle regime.
• the tumor-to-kidney ratio for 131 I-RPS-027 is greater than 2 as soon as 18 h post injection, rises to 3 by 24 h and exceeds 7 by 72 h.
• R 1 , R 2 , and R 3 are each independently H, methyl, benzyl, 4-methoxybenzyl, or tert-butyl;
• R 4 is independently at each occurrence an alkyl group
• n 1 or 2;
• n 0, 1, 2, or 3.
• a composition comprising a compound of any one of Paragraphs A-F and a
• a pharmaceutical composition for treating cancer expressing PSMA comprising an effective amount of the compound Paragraph F, wherin the effective amount is an amount effective for treating the cancer.
• the pharmaceutical composition of Paragraph H wherein the cancer is glioma, cervical carcinoma, vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary, gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer (such as castration resistant prostate cancer).
• a method comprising administering a compound of Paragraph F to a subject suffering from a cancer expressing PSMA.
• carcinoma vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary, gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer (such as castration resistant prostate cancer).
• parenteral administration preferably intravenous administration.
• R 5 , R 6 , and R 7 are each independently H, methyl, benzyl, 4-methoxybenzyl, or tert-butyl;
• R 8 is independently at each occurrence an alkyl group
• W 1 is a bond or - H-alkylene-
• p 0, 1, 2, or 3.
• composition comprising a compound of any one of Paragraphs N-R and a
• a pharmaceutical composition for treating cancer expressing PSMA comprising an effective amount of the compound of Paragraph R and a
• composition wherin the effective amount is an amount effective for treating the cancer.
• U The pharmaceutical composition of Paragraph T, wherein the cancer is glioma, cervical carcinoma, vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary, gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer (such as castration resistant prostate cancer).
• the cancer is glioma, cervical carcinoma, vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary, gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer (such as castration resistant prostate cancer).
• V A method comprising administering a compound of Paragraph R to a subject suffering from cancer expressing PSMA.
• X The method of Paragraph V or Paragraph W, wherein the cancer is glioma, cervical carcinoma, vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary, gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer (such as castration resistant prostate cancer).
• the cancer is glioma, cervical carcinoma, vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary, gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer (such as castration resistant prostate cancer).
• parenteral administration preferably intravenous administration.
• PSMA prostate specific membrane antigen
• a first therapeutic agent comprising a PMSA targeting moiety and a human serum albumin binding moiety to a subject with one or more cancer tumors, where the human serum albumin binding moiety includes a radionuclide;
• glutamate-urea-glutamate moiety or a glutamate-urea-lysine moiety.
• Paragraph Z or Paragraph AA wherein the cancer is glioma, cervical carcinoma, vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary, gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer (such as castration resistant prostate cancer).
• the cancer is glioma, cervical carcinoma, vulvar carcinoma, endometrial carcinoma, primary ovarian carcinoma, metastatic ovarian carcinoma, non-small cell lung cancer, small cell lung cancer, bladder cancer, colon cancer, primary, gastric adenocarcinoma, primary colorectal adenocarcinoma, renal cell carcinoma, or prostate cancer (such as castration resistant prostate cancer).
• AD The method of any one of Paragraphs Z-AC, wherein the human serum albumin binding moiety includes a 4-( 124 I)-substituted, a 4-( 125 I)-substituted, a 4-( 131 I)-substituted, or a 4-( 211 At)-substituted phenyl moiety.
• modifying the first therapeutic agent comprises lengthening or shortening a hydrocarbon chain of the human serum albumin binding moiety.
• AI The method of any one of Paragraphs Z-AH, wherein the modifying the first therapeutic agent comprises conjugating a polyalkane glycol, polyethylene amine (PEI), polyglycine, carbohydrate polymer, amino acid polymer, polyvinyl pyrolidone, a fatty acid, a fatty acid ester group, or a combination of any two or more thereof to the human serum albumin binding moiety.
• PEI polyethylene amine
• polyglycine carbohydrate polymer
• amino acid polymer polyvinyl pyrolidone
• a fatty acid a fatty acid ester group
• a combination of any two or more thereof to the human serum albumin binding moiety.
• polyalkane glycol polyethylene amine (PEI), polyglycine, carbohydrate polymer, amino acid polymer, polyvinyl pyrolidone, a fatty acid, a fatty acid ester group, or a combination of any two or more thereof between the PSMA-targeting moiety and the human serum albumin binding moiety.
• PEI polyethylene amine
• polyglycine polyglycine
• carbohydrate polymer amino acid polymer
• polyvinyl pyrolidone polyvinyl pyrolidone
• a fatty acid a fatty acid ester group
• a combination of any two or more thereof between the PSMA-targeting moiety and the human serum albumin binding moiety or a combination of any two or more thereof between the PSMA-targeting moiety and the human serum albumin binding moiety.
• AK The method of Paragraph AI or Paragraph AJ, wherein the conjugating step comprises conjugating a polyalkane glycol, polyethylene amine (PEI), polyglycine, carbohydrate polymer, amino acid polymer, polyvinyl pyrolidone, a fatty acid, a fatty acid ester group, or a combination of any two or more thereof at a position on the the human serum albumin binding moiety that is distal to the PSMA-targeting moiety.
• PEI polyethylene amine
• Pglycine polyglycine
• carbohydrate polymer amino acid polymer
• polyvinyl pyrolidone polyvinyl pyrolidone
• a fatty acid a fatty acid ester group
• a combination of any two or more thereof at a position on the human serum albumin binding moiety that is distal to the PSMA-targeting moiety.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Physics & Mathematics (AREA)
• Epidemiology (AREA)
• Cell Biology (AREA)
• Biochemistry (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Analytical Chemistry (AREA)
• Food Science & Technology (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Optics & Photonics (AREA)
• Oncology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Reproductive Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Endocrinology (AREA)
• Biophysics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Publications (1)

Family

ID=60675799

Family Applications (1)

Country Status (10)

Cited By (2)

Families Citing this family (8)

Citations (4)

Family Cites Families (28)

• 2017
  • 2017-06-22 CN CN201780046339.7A patent/CN109843339B/zh active Active
  • 2017-06-22 JP JP2018567684A patent/JP7317505B2/ja active Active
  • 2017-06-22 KR KR1020197001426A patent/KR102513698B1/ko active Active
  • 2017-06-22 SG SG11201811482YA patent/SG11201811482YA/en unknown
  • 2017-06-22 EP EP25153047.3A patent/EP4520745A3/en active Pending
  • 2017-06-22 CA CA3028978A patent/CA3028978A1/en active Pending
  • 2017-06-22 EP EP17816235.0A patent/EP3474903B1/en active Active
  • 2017-06-22 KR KR1020237009535A patent/KR102864909B1/ko active Active
  • 2017-06-22 WO PCT/US2017/038832 patent/WO2017223357A1/en not_active Ceased
  • 2017-06-22 AU AU2017281364A patent/AU2017281364B2/en active Active
  • 2017-06-22 US US15/630,808 patent/US10179117B2/en active Active
  • 2017-06-22 CN CN202310698783.4A patent/CN117069621A/zh active Pending
• 2018
  • 2018-12-20 IL IL263863A patent/IL263863B/en unknown
• 2019
  • 2019-01-11 US US16/246,422 patent/US10716772B2/en active Active
• 2020
  • 2020-06-19 US US16/906,956 patent/US12186288B2/en active Active
• 2023
  • 2023-04-04 JP JP2023060583A patent/JP2023103205A/ja active Pending
  • 2023-06-08 AU AU2023203581A patent/AU2023203581B2/en active Active
• 2025
  • 2025-01-06 US US19/011,473 patent/US20260091008A1/en active Pending
  • 2025-07-10 JP JP2025116381A patent/JP2025148450A/ja active Pending

Patent Citations (4)

Non-Patent Citations (29)

Also Published As

Similar Documents

Legal Events